- Home
- TEI vs ACIU Comparison
TEI vs ACIU Comparison
Compare TEI & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEI
- ACIU
- Stock Information
- Founded
- TEI 1993
- ACIU 2003
- Country
- TEI United States
- ACIU Switzerland
- Employees
- TEI N/A
- ACIU N/A
- Industry
- TEI Finance Companies
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- TEI Finance
- ACIU Health Care
- Exchange
- TEI Nasdaq
- ACIU Nasdaq
- Market Cap
- TEI 262.1M
- ACIU 305.7M
- IPO Year
- TEI N/A
- ACIU 2016
- Fundamental
- Price
- TEI $5.35
- ACIU $3.19
- Analyst Decision
- TEI
- ACIU Strong Buy
- Analyst Count
- TEI 0
- ACIU 2
- Target Price
- TEI N/A
- ACIU $12.00
- AVG Volume (30 Days)
- TEI 142.4K
- ACIU 140.1K
- Earning Date
- TEI 01-01-0001
- ACIU 11-05-2024
- Dividend Yield
- TEI 10.51%
- ACIU N/A
- EPS Growth
- TEI N/A
- ACIU N/A
- EPS
- TEI N/A
- ACIU N/A
- Revenue
- TEI N/A
- ACIU $48,505,404.00
- Revenue This Year
- TEI N/A
- ACIU N/A
- Revenue Next Year
- TEI N/A
- ACIU $938.44
- P/E Ratio
- TEI N/A
- ACIU N/A
- Revenue Growth
- TEI N/A
- ACIU 4097200.00
- 52 Week Low
- TEI $4.35
- ACIU $2.25
- 52 Week High
- TEI $5.39
- ACIU $5.14
- Technical
- Relative Strength Index (RSI)
- TEI 37.73
- ACIU 50.14
- Support Level
- TEI $5.32
- ACIU $2.80
- Resistance Level
- TEI $5.63
- ACIU $3.88
- Average True Range (ATR)
- TEI 0.10
- ACIU 0.22
- MACD
- TEI -0.01
- ACIU 0.04
- Stochastic Oscillator
- TEI 10.32
- ACIU 36.11
About TEI Templeton Emerging Markets Income Fund Inc.
Templeton Emerging Markets Income Fund is a closed-end fund. It seeks high, current income, with a secondary goal of capital appreciation, by investing, under normal market conditions. The company's investment portfolio includes Foreign Government and Agency Securities; Quasi-Sovereign and Corporate Bonds; Common Stocks and Other Equity Interests, and Short-Term Investments and Money Market Funds.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.